Temazepam
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Temazepam
Temazepam
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Temazepam, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. In Australia, Temazepam is listed as “Marketed (valid licences: 1 of 1)”.
Quick overview
| Item | Content |
|---|---|
| Known uses among model candidates | 0 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 2088X | Temtabs | Tablet 10 mg | Valid |
Safety Considerations
- Drug Interactions (100 recorded; main ones shown):
- Major: morphine, liposomal morphine (additive central nervous system and respiratory depression).
- Moderate: bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine, teduglutide.
- Minor: antacids and magnesium or calcium products (e.g. aluminium hydroxide, calcium carbonate, magnesium oxide, magnesium hydroxide).
- Literature signals: rebound insomnia on discontinuation, dependence risk after short prescriptions, abuse and injecting misuse (including gel capsule formulations in Australia), and safety concerns in older adults.
Please also refer to the TGA-approved Product Information (PI) for full warnings and precautions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.